Report cover image

Global Eosinophilic Esophagitis Drug Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 193 Pages
SKU # APRC20284079

Description

Summary

According to APO Research, The global Eosinophilic Esophagitis Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Eosinophilic Esophagitis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Eosinophilic Esophagitis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Eosinophilic Esophagitis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Eosinophilic Esophagitis Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Eosinophilic Esophagitis Drug include Adare Pharmaceuticals, Calypso, Celgene, DBV Technologies, Dr. Falk Pharma, Quorum Innovations, Regeneron, AstraZeneca and Bayer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Eosinophilic Esophagitis Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Eosinophilic Esophagitis Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Eosinophilic Esophagitis Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Eosinophilic Esophagitis Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Eosinophilic Esophagitis Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Eosinophilic Esophagitis Drug sales, projected growth trends, production technology, application and end-user industry.

Eosinophilic Esophagitis Drug Segment by Company

Adare Pharmaceuticals
Calypso
Celgene
DBV Technologies
Dr. Falk Pharma
Quorum Innovations
Regeneron
AstraZeneca
Bayer
GSK
Takeda
Eosinophilic Esophagitis Drug Segment by Type

Budesonide
Fluticasone
Others
Eosinophilic Esophagitis Drug Segment by Application

Hospitals
Clinics
Drugstore
Eosinophilic Esophagitis Drug Segment by Region

North America
United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Eosinophilic Esophagitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Eosinophilic Esophagitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Eosinophilic Esophagitis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Eosinophilic Esophagitis Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Eosinophilic Esophagitis Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Eosinophilic Esophagitis Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Eosinophilic Esophagitis Drug Market by Type
1.2.1 Global Eosinophilic Esophagitis Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Budesonide
1.2.3 Fluticasone
1.2.4 Others
1.3 Eosinophilic Esophagitis Drug Market by Application
1.3.1 Global Eosinophilic Esophagitis Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Drugstore
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Eosinophilic Esophagitis Drug Market Dynamics
2.1 Eosinophilic Esophagitis Drug Industry Trends
2.2 Eosinophilic Esophagitis Drug Industry Drivers
2.3 Eosinophilic Esophagitis Drug Industry Opportunities and Challenges
2.4 Eosinophilic Esophagitis Drug Industry Restraints
3 Global Market Growth Prospects
3.1 Global Eosinophilic Esophagitis Drug Revenue Estimates and Forecasts (2020-2031)
3.2 Global Eosinophilic Esophagitis Drug Revenue by Region
3.2.1 Global Eosinophilic Esophagitis Drug Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Eosinophilic Esophagitis Drug Revenue by Region (2020-2025)
3.2.3 Global Eosinophilic Esophagitis Drug Revenue by Region (2026-2031)
3.2.4 Global Eosinophilic Esophagitis Drug Revenue Market Share by Region (2020-2031)
3.3 Global Eosinophilic Esophagitis Drug Sales Estimates and Forecasts 2020-2031
3.4 Global Eosinophilic Esophagitis Drug Sales by Region
3.4.1 Global Eosinophilic Esophagitis Drug Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Eosinophilic Esophagitis Drug Sales by Region (2020-2025)
3.4.3 Global Eosinophilic Esophagitis Drug Sales by Region (2026-2031)
3.4.4 Global Eosinophilic Esophagitis Drug Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Eosinophilic Esophagitis Drug Revenue by Manufacturers
4.1.1 Global Eosinophilic Esophagitis Drug Revenue by Manufacturers (2020-2025)
4.1.2 Global Eosinophilic Esophagitis Drug Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Eosinophilic Esophagitis Drug Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Eosinophilic Esophagitis Drug Sales by Manufacturers
4.2.1 Global Eosinophilic Esophagitis Drug Sales by Manufacturers (2020-2025)
4.2.2 Global Eosinophilic Esophagitis Drug Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Eosinophilic Esophagitis Drug Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Eosinophilic Esophagitis Drug Sales Price by Manufacturers (2020-2025)
4.4 Global Eosinophilic Esophagitis Drug Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Eosinophilic Esophagitis Drug Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Eosinophilic Esophagitis Drug Manufacturers, Product Type & Application
4.7 Global Eosinophilic Esophagitis Drug Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Eosinophilic Esophagitis Drug Market CR5 and HHI
4.8.2 2024 Eosinophilic Esophagitis Drug Tier 1, Tier 2, and Tier 3
5 Eosinophilic Esophagitis Drug Market by Type
5.1 Global Eosinophilic Esophagitis Drug Revenue by Type
5.1.1 Global Eosinophilic Esophagitis Drug Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Eosinophilic Esophagitis Drug Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2020-2031)
5.2 Global Eosinophilic Esophagitis Drug Sales by Type
5.2.1 Global Eosinophilic Esophagitis Drug Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Eosinophilic Esophagitis Drug Sales by Type (2020-2031) & (W Units)
5.2.3 Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2020-2031)
5.3 Global Eosinophilic Esophagitis Drug Price by Type
6 Eosinophilic Esophagitis Drug Market by Application
6.1 Global Eosinophilic Esophagitis Drug Revenue by Application
6.1.1 Global Eosinophilic Esophagitis Drug Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Eosinophilic Esophagitis Drug Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2020-2031)
6.2 Global Eosinophilic Esophagitis Drug Sales by Application
6.2.1 Global Eosinophilic Esophagitis Drug Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Eosinophilic Esophagitis Drug Sales by Application (2020-2031) & (W Units)
6.2.3 Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2020-2031)
6.3 Global Eosinophilic Esophagitis Drug Price by Application
7 Company Profiles
7.1 Adare Pharmaceuticals
7.1.1 Adare Pharmaceuticals Comapny Information
7.1.2 Adare Pharmaceuticals Business Overview
7.1.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product Portfolio
7.1.5 Adare Pharmaceuticals Recent Developments
7.2 Calypso
7.2.1 Calypso Comapny Information
7.2.2 Calypso Business Overview
7.2.3 Calypso Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Calypso Eosinophilic Esophagitis Drug Product Portfolio
7.2.5 Calypso Recent Developments
7.3 Celgene
7.3.1 Celgene Comapny Information
7.3.2 Celgene Business Overview
7.3.3 Celgene Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Celgene Eosinophilic Esophagitis Drug Product Portfolio
7.3.5 Celgene Recent Developments
7.4 DBV Technologies
7.4.1 DBV Technologies Comapny Information
7.4.2 DBV Technologies Business Overview
7.4.3 DBV Technologies Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 DBV Technologies Eosinophilic Esophagitis Drug Product Portfolio
7.4.5 DBV Technologies Recent Developments
7.5 Dr. Falk Pharma
7.5.1 Dr. Falk Pharma Comapny Information
7.5.2 Dr. Falk Pharma Business Overview
7.5.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Dr. Falk Pharma Eosinophilic Esophagitis Drug Product Portfolio
7.5.5 Dr. Falk Pharma Recent Developments
7.6 Quorum Innovations
7.6.1 Quorum Innovations Comapny Information
7.6.2 Quorum Innovations Business Overview
7.6.3 Quorum Innovations Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Quorum Innovations Eosinophilic Esophagitis Drug Product Portfolio
7.6.5 Quorum Innovations Recent Developments
7.7 Regeneron
7.7.1 Regeneron Comapny Information
7.7.2 Regeneron Business Overview
7.7.3 Regeneron Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Regeneron Eosinophilic Esophagitis Drug Product Portfolio
7.7.5 Regeneron Recent Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Comapny Information
7.8.2 AstraZeneca Business Overview
7.8.3 AstraZeneca Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 AstraZeneca Eosinophilic Esophagitis Drug Product Portfolio
7.8.5 AstraZeneca Recent Developments
7.9 Bayer
7.9.1 Bayer Comapny Information
7.9.2 Bayer Business Overview
7.9.3 Bayer Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Bayer Eosinophilic Esophagitis Drug Product Portfolio
7.9.5 Bayer Recent Developments
7.10 GSK
7.10.1 GSK Comapny Information
7.10.2 GSK Business Overview
7.10.3 GSK Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 GSK Eosinophilic Esophagitis Drug Product Portfolio
7.10.5 GSK Recent Developments
7.11 Takeda
7.11.1 Takeda Comapny Information
7.11.2 Takeda Business Overview
7.11.3 Takeda Eosinophilic Esophagitis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Takeda Eosinophilic Esophagitis Drug Product Portfolio
7.11.5 Takeda Recent Developments
8 North America
8.1 North America Eosinophilic Esophagitis Drug Market Size by Type
8.1.1 North America Eosinophilic Esophagitis Drug Revenue by Type (2020-2031)
8.1.2 North America Eosinophilic Esophagitis Drug Sales by Type (2020-2031)
8.1.3 North America Eosinophilic Esophagitis Drug Price by Type (2020-2031)
8.2 North America Eosinophilic Esophagitis Drug Market Size by Application
8.2.1 North America Eosinophilic Esophagitis Drug Revenue by Application (2020-2031)
8.2.2 North America Eosinophilic Esophagitis Drug Sales by Application (2020-2031)
8.2.3 North America Eosinophilic Esophagitis Drug Price by Application (2020-2031)
8.3 North America Eosinophilic Esophagitis Drug Market Size by Country
8.3.1 North America Eosinophilic Esophagitis Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Eosinophilic Esophagitis Drug Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Eosinophilic Esophagitis Drug Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Eosinophilic Esophagitis Drug Market Size by Type
9.1.1 Europe Eosinophilic Esophagitis Drug Revenue by Type (2020-2031)
9.1.2 Europe Eosinophilic Esophagitis Drug Sales by Type (2020-2031)
9.1.3 Europe Eosinophilic Esophagitis Drug Price by Type (2020-2031)
9.2 Europe Eosinophilic Esophagitis Drug Market Size by Application
9.2.1 Europe Eosinophilic Esophagitis Drug Revenue by Application (2020-2031)
9.2.2 Europe Eosinophilic Esophagitis Drug Sales by Application (2020-2031)
9.2.3 Europe Eosinophilic Esophagitis Drug Price by Application (2020-2031)
9.3 Europe Eosinophilic Esophagitis Drug Market Size by Country
9.3.1 Europe Eosinophilic Esophagitis Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Eosinophilic Esophagitis Drug Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Eosinophilic Esophagitis Drug Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
10 China
10.1 China Eosinophilic Esophagitis Drug Market Size by Type
10.1.1 China Eosinophilic Esophagitis Drug Revenue by Type (2020-2031)
10.1.2 China Eosinophilic Esophagitis Drug Sales by Type (2020-2031)
10.1.3 China Eosinophilic Esophagitis Drug Price by Type (2020-2031)
10.2 China Eosinophilic Esophagitis Drug Market Size by Application
10.2.1 China Eosinophilic Esophagitis Drug Revenue by Application (2020-2031)
10.2.2 China Eosinophilic Esophagitis Drug Sales by Application (2020-2031)
10.2.3 China Eosinophilic Esophagitis Drug Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Eosinophilic Esophagitis Drug Market Size by Type
11.1.1 Asia Eosinophilic Esophagitis Drug Revenue by Type (2020-2031)
11.1.2 Asia Eosinophilic Esophagitis Drug Sales by Type (2020-2031)
11.1.3 Asia Eosinophilic Esophagitis Drug Price by Type (2020-2031)
11.2 Asia Eosinophilic Esophagitis Drug Market Size by Application
11.2.1 Asia Eosinophilic Esophagitis Drug Revenue by Application (2020-2031)
11.2.2 Asia Eosinophilic Esophagitis Drug Sales by Application (2020-2031)
11.2.3 Asia Eosinophilic Esophagitis Drug Price by Application (2020-2031)
11.3 Asia Eosinophilic Esophagitis Drug Market Size by Country
11.3.1 Asia Eosinophilic Esophagitis Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Eosinophilic Esophagitis Drug Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Eosinophilic Esophagitis Drug Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Eosinophilic Esophagitis Drug Market Size by Type
12.1.1 SAMEA Eosinophilic Esophagitis Drug Revenue by Type (2020-2031)
12.1.2 SAMEA Eosinophilic Esophagitis Drug Sales by Type (2020-2031)
12.1.3 SAMEA Eosinophilic Esophagitis Drug Price by Type (2020-2031)
12.2 SAMEA Eosinophilic Esophagitis Drug Market Size by Application
12.2.1 SAMEA Eosinophilic Esophagitis Drug Revenue by Application (2020-2031)
12.2.2 SAMEA Eosinophilic Esophagitis Drug Sales by Application (2020-2031)
12.2.3 SAMEA Eosinophilic Esophagitis Drug Price by Application (2020-2031)
12.3 SAMEA Eosinophilic Esophagitis Drug Market Size by Country
12.3.1 SAMEA Eosinophilic Esophagitis Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Eosinophilic Esophagitis Drug Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Eosinophilic Esophagitis Drug Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Eosinophilic Esophagitis Drug Value Chain Analysis
13.1.1 Eosinophilic Esophagitis Drug Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Eosinophilic Esophagitis Drug Production Mode & Process
13.2 Eosinophilic Esophagitis Drug Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Eosinophilic Esophagitis Drug Distributors
13.2.3 Eosinophilic Esophagitis Drug Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.